Clinical trial design

Child with eczema
#Atopic dermatitis #Clinical trial #Clinical trial design #Innovaderm Research #Phase I trial #RAPT Therapeutics

Clinical data supports oral treatment for atopic dermatitis

A new drug for atopic dermatitis (AD) has demonstrated a positive clinical effect and improvements in various efficacy endpoints after four weeks of treatment. The Phase Ia/IIb study was designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and CCR4 surface receptor occupancy of zelnecirnon in eligible… Read More

#News

AI clinical trials concept
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Clinical trial design #Clinical trials

Decoding diseases: The AI renaissance in clinical trials

Listen to this article on the DDW Podcast: Deepika Khedekar, Associate Centralized Clinical Lead at IQVIA, explains how artificial intelligence could make clinical trials more accurate, accessible and standardised. Over 19 million1 hearts succumb to cardiovascular disease yearly, while around 10 million2 lives are claimed by cancer every year. To put… Read More

#Exclusive Content

#Clinical trial #Clinical trial design #Clinical trials #Drug development

Free clinical trial health check to bring drugs to market faster

A new free service will offer insights in under ten days to sponsors conducting clinical trials, identifying potential ‘zombie trials’ and providing actionable recommendations for failing trials. The Health Check and Trial Rescue Service is an initiative of data software and services company Phesi. The service… Read More

#News

MHRA
#Clinical Trial Authorisation #Clinical trial design #Clinical trials #MHRA #Phase III trial #UK

UK regulator cuts late-stage clinical trial approval time to two weeks

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has revealed plans to reduce the time taken to approve the lowest-risk clinical trials by more than 50%. According to the plans, initial applications for the lowest-risk Phase III and IV trials will be processed by the MHRA within 14 days… Read More

#News #Regulatory

Patient advocacy group
#Cancer #Cancer research #Clinical trial design #Clinical trials #Oncology #Patient centricity

Patient groups issue call to action on patient-centric clinical trials

A new whitepaper has introduced the concept of ‘cross-over’ options in cancer clinical trials, as a way to make trials more patient-centric in design. ‘Cross-over arms in oncology clinical trials: An important consideration for patients’ was published by the Cholangiocarcinoma Foundation (CCF) with the aim of… Read More

#News

#AI / data analytics / healthtech / informatics #Clinical trial design #Clinical trials #Oncology #Phase II trial

A third of clinical trials cancelled during Phase II

Analysis of 13,490 clinical trials finds almost a third have been cancelled during Phase II amidst an overall decline in clinical development productivity. Data analytics company Phesi has released the results of its mid-year global analysis of all clinical trials conducted in 2023 to date. Read More

#News #Trending News

Cancer research lab
#Cancer research #Cancer Research UK #Clinical trial design #Oncology #Precision medicine

Cancer Research UK joins precision cancer medicine consortium

Cancer Research UK has joined the PRIME-ROSE project, a Europe-wide effort to boost patient access to precision cancer medicine (PCM). The PRIME-ROSE consortium consists of 24 partners, including nine beneficiaries and fifteen associated partners who will come together over the course of five years and work… Read More

#Cancer Research #News

Magic mushrooms
#Clinical trial design #Clinical trials #FDA #Psychedelics

FDA recommendations to inform psychedelic drug development

The US Food and Drug Administration (FDA) has published new draft guidance to highlight fundamental considerations to researchers investigating the use of psychedelic drugs for the potential treatment of medical conditions, including psychiatric or substance use disorders. This is the first FDA draft guidance that presents considerations to industry for… Read More

#News #Regulatory

#Cancer research #Clinical trial design #Clinical trials #FDA #Phase I trial

New DDW Highlights podcast for 12 June 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  There has been some interesting news related to clinical trials this week, with the announcement that… Read More

#News

#Cancer research #Clinical trial design #Clinical trials #FDA #Phase I trial

This week in drug discovery (5-9 June)

News round-up for 5-9 June by DDW Digital Content Editor Diana Spencer. There has been some interesting news related to clinical trials this week, with the announcement that the FDA has published draft guidance to modernise the design and conduct of studies, and the failure of… Read More

#News

FDA
#AI / data analytics / healthtech / informatics #Clinical trial design #Clinical trials #Digitalisation #FDA

FDA announces additional steps to modernise clinical trials

The US Food and Drug Administration has published draft guidance with updated recommendations for good clinical practices (GCPs) to modernise the design and conduct of clinical trials. The updates are intended to help pave the way for more efficient clinical trials. The draft guidance is adopted from the International Council… Read More

#Editor's Choice #News #Regulatory

Diversity
#Clinical trial design #Clinical trials #Diversity #Inato #Inclusivity #Investment #Oncology

$20 million in new funding to make clinical trials more inclusive

Clinical trial technology platform Inato, based in Paris, France, has closed a $20 million Series A funding from investors including Cathay Innovation, Obvious Ventures, La Maison and Top Harvest Capital. With the new funding, Inato will advance its diversity product offering to meet the new FDA requirements. The company will… Read More

#Business & Investment #News #Start-up Zone

Clinical trial
#ABPI #Clinical trial design #Clinical trials #MHRA #UK

Biggest overhaul of UK clinical trial regulation for 20 years

A series of new measures will be introduced by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to make it faster and easier to gain approval and run clinical trials in the UK. These changes represent the biggest overhaul in UK clinical trials regulation in… Read More

#News

Patient advocacy group
#Clinical trial design #Clinical trials #Decentralised clinical trials #Drug development #Patient centricity #Rare disease

Recruiting and retaining patients for successful drug development

Craig Stevens, Senior Patient Engagement Specialist, and Amanda Henkel, VP, Strategy from MEDiSTRAVA (an Inizio Company), delve into the challenges and opportunities that surround clinical trial design for rare diseases. The drug development process requires collaboration at all stages, and is particularly important in the rare disease setting, where in… Read More

#Exclusive Content

#Cancer research #Clinical trial design #Clinical trials #Drug discovery #Gene therapy #Oncology

Podcast: Key stories from the drug discovery industry

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Perhaps most interestingly this week, after previous caution over in vivo… Read More

#News

Dermatology patient
#Clinical trial design #Clinical trials #Decentralised clinical trials #ICON #LEO Pharma

LEO partners with ICON to offer patient-centric dermatology trials

LEO Pharma and ICON have formed a strategic partnership that will enable LEO to offer clinical trials within medical dermatology that are patient-centric and cost effective. The partnership will operate under the acronym of PACE, reflecting the requirement to move quickly to address today’s clinical development challenges. Read More

#News